-
Genetic Testing Gaps
Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling.
by Kate Yandell
-
Patient Advocates Tune in for Precision Medicine Primer
Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.
by Kevin McLaughlin
-
Liquid Biopsies May Ease Enrollment in Clinical Trials
A study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.
by Emma Yasinski
-
Taking Drug Dosing Off Autopilot
Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.
by Marcus A. Banks
-
Targeted Therapy for Early-Stage Lung Cancer?
A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.
by Ashley P. Taylor
-
What is a Super Responder?
Researchers are investigating why certain patients have an exceptional response to a particular drug.
by Bradley Jones
-
Tumor Testing May Help Guide Pancreatic Cancer Treatment
For a small group of pancreatic cancer patients who were able to receive therapies targeting the molecular alterations in their tumors, these matched therapies were associated with longer life.
by Cheryl Platzman Weinstock
-
Despite Generic Imatinib, Cost of Treating CML Remains High
The arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.
by Anna Azvolinsky
-
New Drugs for an Elusive Cancer Target
Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.
by Anna Azvolinsky
-
Clinical Trials: An African American Survivor’s Experience
Melvin Mann benefited from joining a pivotal clinical trial for chronic myelogenous leukemia, but participation came with logistical challenges.
by Melvin Mann
Cancer Talk
Navigating Out of Financial Toxicity
People with cancer face an increased risk of financial hardship. Education and expert guidance can offer patients a lifeline.
by Thomas Celona
Taking Answers HomeAdvocates bring the patient perspective to the AACR Annual Meeting 2024 and leave with tools to better communicate advances in care to others.
by Eric Fitzsimmons
Lifestyle Choices and CancerWhat people eat and drink and their level of physical activity can affect their risk of having cancer. New interventions aim to reduce risk factors.
by Kevin McLaughlin
Improving Colorectal Cancer Screening OptionsTests currently in development seek to offer greater accuracy and reach more people.
by Eric Fitzsimmons